Lupin receives approval from U.S. FDA for Metoprolol Succinate Extended-Release Tablets USP

Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Metoprolol Succinate Extended-Release Tablets USP, 25 mg, 50 mg, 100 mg, and 200 mg, to market a generic equivalent of Toprol-XL® Tablets, 25 mg, 50 mg, 100 mg and 200 mg of Sequel Therapeutics, LLC. This product will be manufactured at Lupin's Pithampur facility in India.

Metoprolol Succinate Extended-Release Tablets USP (RLD Toprol-XL®) had estimated annual sales of USD 305 million in the U.S. (IQVIA MAT June 2023).

Shares of Lupin Limited was last trading in BSE at Rs. 1081.70 as compared to the previous close of Rs. 1076.95. The total number of shares traded during the day was 90529 in over 4824 trades.

The stock hit an intraday high of Rs. 1105.80 and intraday low of 1077.35. The net turnover during the day was Rs. 98894131.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 USFDA ANDA Approval MetroprololSuccinate ExtendedReleaseTablets